Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease of serum dipeptidylpeptidase activity in severe sepsis patients: relationship to procalcitonin.

Andreas Bergmann1, Claude Bohuon

  • 1Brahms Diagnostica, Komturstrasse 19-20, D 12099, Berlin, Germany.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|May 29, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and non-clinical characterization of Procizumab (invobenitug): a humanized antibody neutralizing circulating DPP3.

mAbs·2026
Same author

Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.

mAbs·2026
Same author

The Hippo paradox: how growth suppression drives tumor growth.

EMBO reports·2026
Same author

AlphaFold3-based modeling uncovers the dynamic structural interface between full-length IAP antagonists and DIAP1 for apoptosis regulation in Drosophila.

Cell communication and signaling : CCS·2026
Same author

Calcium signaling regulates apoptosis-induced proliferation in Drosophila.

PLoS biology·2026
Same author

AlphaFold3-based modeling uncovers the dynamic structural interface between full-length IAP antagonists and DIAP1 for apoptosis regulation in <i>Drosophila</i>.

bioRxiv : the preprint server for biology·2026

Severe sepsis patients show decreased dipeptidyl peptidase IV (DPP IV) activity, potentially linked to increased procalcitonin levels and altered immunomodulation. Further research is needed to confirm the clinical significance of these sepsis-related enzymatic changes.

Area of Science:

  • Biochemistry
  • Immunology
  • Critical Care Medicine

Background:

  • Dipeptidyl peptidase IV (DPP IV) is an enzyme involved in various physiological processes.
  • Severe sepsis is a life-threatening condition characterized by dysregulated host response to infection.
  • Procalcitonin is a biomarker often elevated in bacterial infections and sepsis.

Purpose of the Study:

  • To investigate the activity of DPP IV in patients with severe sepsis.
  • To explore the relationship between DPP IV activity, procalcitonin levels, and potential immunomodulatory changes in sepsis.

Main Methods:

  • Enzyme activity assays were performed on patient samples.
  • DPP IV activity was correlated with procalcitonin levels.
  • Potential confounding factors, such as other DPP IV substrates, were considered.

Related Experiment Videos

Main Results:

  • A significant decrease in DPP IV activity was observed in patients with severe sepsis.
  • This decrease in DPP IV activity correlated with elevated procalcitonin levels.
  • The presence of high concentrations of other DPP IV substrates may contribute to the observed decrease.

Conclusions:

  • DPP IV activity is significantly reduced in severe sepsis, correlating with increased procalcitonin.
  • This reduction may be influenced by elevated levels of other DPP IV substrates.
  • The findings suggest a potential link between DPP IV activity changes and immunomodulation in sepsis, warranting further investigation into clinical significance.